Equibles does not estimate personal net worth.
Get an email with a short summary when Amneal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMRX alertsAnastasios Konidaris is recorded as CFO at Amneal Pharmaceuticals, Inc. (AMRX). The newest filing on record that lists Anastasios Konidaris as CFO at Amneal Pharmaceuticals, Inc. (AMRX) is dated March 25, 2026. The proxy statement of Amneal Pharmaceuticals, Inc. reports total compensation of $3,293,494 for Anastasios Konidaris in fiscal 2025, including a base salary of $600,750. Disclosed compensation is on record for 6 fiscal years. Anastasios Konidaris has spoken on 5 earnings calls across 1 company, most recently for Amneal Pharmaceuticals, Inc. on May 3, 2024. Amneal Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amneal Pharmaceuticals, Inc. includes Chintu Patel (CEO and Board Member), Chirag Patel (CEO and Board Member), Paul Meister (Chairman and Board Member) and 7 others.
“At a high level, our diversified business is driving sustainable higher levels of revenues and profits and continued deleveraging. Our first quarter results were excellent, with total net revenue of $659 million, up 18%.”
“Our third quarter financial results reflect solid and consistent performance driven by our increasingly diverse product portfolio. For the third quarter, we reported total net revenue of $546 million, adjusted gross margin of 44%, adjusted EBITDA of $126 million, and adjusted diluted EPS of $0.14.”
“Our second quarter financial results were in line with our expectations and reflect solid top and bottom line performance and substantial sequential acceleration.”
“Our first quarter financial momentum reflects the relevance and diversification of our product portfolio, successful new product launches, and our focus on execution and driving efficiencies.”
“Earlier this morning, we issued a press release reporting our quarterly results.”
Start not stated–present
Last confirmed March 25, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $600,750 | $3,293,494 |
| 2024 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $580,731 | $2,852,333 |
| 2023 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $563,327 | $1,891,266 |
| 2022 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $550,000 | $2,733,186 |
| 2021 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $550,000 | $2,663,996 |
| 2020 | Amneal Pharmaceuticals, Inc. (AMRX) | EVP & Chief Financial Officer | $427,308 | $2,508,499 |
